Enzyme reconstitution/replacement therapy for lysosomal storage diseases

Current Opinion in Pediatrics

Volumn 19, Issue 6, 2007, Pages 628-635

  Burrow, T Andrew ^b   Hopkin, Robert J ^b   Leslie, Nancy D ^b   Tinkle, Bradley T ^b   Grabowski, Gregory A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

Fabry disease; Gaucher disease; Glycosphingolipids; Lysosomes; Mucopolysaccharidoses; Pompe disease

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALGLUCERASE; ALPHA GALACTOSIDASE; ELAPRASE; GALSULFASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSYLCERAMIDASE; IDURONATE 2 SULFATASE; IMIGLUCERASE; LARONIDASE; LEVO IDURONIDASE; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; UNCLASSIFIED DRUG;

ANAPHYLAXIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENZYME RECONSTITUTION; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LYSOSOME STORAGE DISEASE; MUCOPOLYSACCHARIDOSIS; PHENOTYPE; PHYSICIAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ALPHA-GALACTOSIDASE; CHILD; COST OF ILLNESS; DISEASE PROGRESSION; FABRY DISEASE; GLUCOSYLCERAMIDASE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; IDURONATE SULFATASE; LYSOSOMAL STORAGE DISEASES; MUCOPOLYSACCHARIDOSES;

EID: 36348943468     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3282f161f2     Document Type: Review

References (55)

1. Kornfeld S. Structure and function of the mannose 6-phosphate/insulin like growth factor II receptors. Annu Rev Biochem 1992; 61:307-330.
2. Leinekugel P, Michel S, Conzelmann E, Sandhoff K. Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 1992; 88:513-523.
3. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited diseases. 8th ed. New York: McGraw-Hill; 2001. pp. 3635-3668.
4. Grabowski GA, Kolodny EH, Weinreb NJ, et al. Gaucher disease: phenotypic and genetic variation. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The online metabolic and molecular bases of inherited diseases [online]. New York: McGraw-Hill; 2006.; chapter 146.1. Available at http://genetics.accessmedicine.com.
5. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324:1464-1470.
6. Grabowski GA, Barton NW, Pastores G, Banerjee TK, et al. Enzyme therapy in Gaucher disease type 1: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122:33-39.
7. Pastores GM, Weinreb NJ, Aerts H, Andria G, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41 (4 Suppl 5):4-14.
8. Charrow J, Dulisse B, Grabowski GA, Weinreb NJ. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007; 71:205-211.
9. Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 2007; 22:119-126.
10. Brady RO, Murray GJ, Moore DF, Schiffmann R. Enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 2001; 24 (Suppl 2):18-24; discussion 11-12.
11. Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004; 144 (5 Suppl):S20-S26.
12. Ries M, Ramaswami U, Parini R, Lindblad B, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 2003; 162:767-772.
13. Elleder M, Poupetova H, Kozich V. Fetal pathology in Fabry's disease and mucopolysaccharidosis type I. Cesk Patol 1998; 34:7-12.
14. Ries M, Clarke JT, Whybra C, Timmons M, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006; 118:924-932.
15. Ries M, Gupta S, Moore DF, Sachdev V, et al. Pediatric Fabry disease. Pediatrics 2005; 115:e344-e355.
16. Ramaswami U, Whybra C, Parini R, Pintos-Morell G, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006; 95:86-92.
17. Ramaswami U, Wendt S, Pintos-Morell G, Parini R, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007; 96:122-127.
18. Mehta A, Ricci R, Widmer U, Dehout F, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34:236-242.
19. Eng CM, Fletcher J, Wilcox WR, Waldek S, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007; 30:184-192.
20. Hoffmann B, Keshav S. Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr Suppl 2007; 96:84-86.
21. Sodi A, Ioannidis AS, Mehta A, Davey C, et al. Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey. Br J Ophthalmol 2007; 91:210-214.
22. Desnick RJ, Ioannou Y, Eng CM. Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. pp. 3733-3774.
23. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 2001; 24 (Suppl 2):13-14; discussion 1-2.
24. Eng CM, Germain DP, Banikazemi M, Warnock DG, et al. Fabry disease: guidelines for the evaluation and management of multiorgan system involvement. Genet Med 2006; 8:539-548.
25. Moon JC, Sachdev B, Elkington AG, McKenna WJ, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003; 24:2151-2155.
26. Rolfs A, Bottcher T, Zschiesche M, Morris P, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005; 366:1794-1796.
27. Banikazemi M, Bultas J, Waldek S, Wilcox WR, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146:77-86.
28. Moore DF, Krokhin OV, Beavis RC, Ries M, et al. Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities. Proc Natl Acad Sci U S A 2007; 104:2873-2878.
29. Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 2005; 85:255-259.
30. Kishnani PS, Hwu WL, Mandel H, Nicolino M, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006; 148:671-676.
31. Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, et al. The natural course of nonclassic Pompe's disease; a review of 225 published cases. J Neurol 2005; 252:875-884.
32. Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005; 128:671-677.
33. Kikuchi T, Yang HW, Pennybacker M, Ichihara N, et al. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 1998; 101:827-833.
34. Reuser AJ, Van Den Hout H, Bijvoet AG, Kroos MA, et al. Enzyme therapy for Pompe disease: from science to industrial enterprise. Eur J Pediatr 2002; 161 (Suppl 1):S106-S111.
35. Amalfitano A, Bengur AR, Morse RP, Majure JM, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001; 3:132-138.
36. Kishnani PS, Nicolino M, Voit T, Rogers RC, et al. Chinese hamster ovary cellderived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006; 149:89-97.
37. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, et al. Long-term intravenous treatment of Pompe disease with recombinant human alphaglucosidase from milk. Pediatrics 2004; 113:e448-e457.
38. Kishnani PS, Corzo D, Nicolino M, Byrne B, et al. Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007; 68:99-109.
39. Ing RJ, Cook DR, Bengur RA, Williams EA, et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth 2004; 14:514-519.
40. Fukuda T, Ahearn M, Roberts A, Mattaliano RJ, et al. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther 2006; 14:831-839.
41. Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, et al. Characterization of pre and posttreatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 2006; 86:1208-1220. A histopathologic study of infantile Pompe disease in eight patients providing insight into cellular progression of disease and response to ERT.
42. Vellodi A, Young EP, Cooper A, Wraith JE, et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child 1997; 76:92-99.
43. Peters C, Shapiro EG, Anderson J, Henslee-Downey PJ, et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 1998; 91:2601-2608.
44. Guffon N, Souillet G, Maire I, Straczek J, et al. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 1998; 133:119-125.
45. Gassas A, Sung L, Doyle JJ, Clarke JT, et al. Life-threatening pulmonary hemorrhages post bone marrow transplantation in Hurler syndrome. Report of three cases and review of the literature. Bone Marrow Transplant 2003; 32:213-215.
46. Kakkis ED, Muenzer J, Tiller GE, Waber L, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001; 344:182-188.
47. Wraith JE, Clarke LA, Beck M, Kolodny EH, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004; 144:581-588.
48. Sifuentes M, Doroshow R, Hoft R, Mason G, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 2007; 90:171-180. A study evaluating the long-term safety and efficacy of laronidase therapy in five patients after 6 years of therapy.
49. Peters C, Krivit W. Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome). Bone Marrow Transplant 2000; 25:1097-1099.
50. Krivit W. Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr 2002; 49:359-378.
51. Muenzer J, Wraith JE, Beck M, Giugliani R, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8:465-473.
52. Krivit W, Pierpont ME, Ayaz K, Tsai M, et al. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med 1984; 311:1606-1611.
53. Krivit W. Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Treatment by allogenic bone marrow transplantation in 6 patients and potential for autotransplantation bone marrow gene insertion. Int Pediatr 1992; 7:47-52.
54. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007; 120:405-418.
55. Harmatz P, Giugliani R, Schwartz I, Guffon N, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006; 148:533-539.